It is proposed that TKIs may lead to release of tumour associated antigens via tumour cell death, increasing both basal and IFN gamma induced major histocompatibility complex (MHC) class-I presentation which in turn react with T cells causing heightened toxicity. The gene discussed is IFNG; the disease is neoplasm.